HOME >> MEDICINE >> NEWS
Jurys still out on use of marijuana derivative for MS

St. Paul, MN Anecdotal claims of the benefits of marijuana for people with multiple sclerosis (MS) have been around for years, but the few studies on the topic have been small and inconclusive. A new study suggests that marijuana derivatives do not improve MS symptoms, but researchers say more studies need to be done before conclusions can be reached.

At 16 patients, the study is the largest randomized, controlled clinical trial on this topic. The study is published in the May 14 issue of Neurology, the scientific journal of the American Academy of Neurology. The patients were given capsules of a placebo, marijuana plant-extract, or synthetic tetrahydrocannabinol (THC), which is the active ingredient in marijuana, for four weeks each.

The patients had severe spasticity, the MS symptom that some reports have found the most responsive to marijuana treatment. Spasticity, one of the more common symptoms of MS, involves involuntary muscle stiffness and/or spasms.

The study found that both the synthetic THC and the plant-extract were safe for patients, although side effects such as dizziness and headache were more common with plant-extract treatment. The study was designed to determine whether the marijuana derivatives are safe for patients. It was not designed to determine how effective they are in treating MS symptoms.

Due to the limited numbers of patients, we cant draw any definite conclusions, said study author Joep Killestein, MD, of the VU Medical Center in Amsterdam, Netherlands. But these results suggest that synthetic THC and plant-extract do not improve symptoms for MS patients.

There were no differences in the patients level of spasticity while taking placebo and either of the marijuana derivatives, according to neurologist Chris H. Polman, who supervised the study. Patients muscle tone improved while on the drug treatments, but their ratings on a scale measuring overall disability declined. In their own rating of their
'"/>

Contact: Cheryl Alementi
calementi@aan.com
651-695-2737
American Academy of Neurology
13-May-2002


Page: 1 2

Related medicine news :

1. Archival virus still necessitates life-long antiretroviral therapy
2. HIV infection still on the rise
3. Colonoscopy still most effective colorectal cancer screening method
4. New rights to access, but for most transparency is still as clear as mud
5. Tide of new nurses rises but shortages still loom large
6. Teenage smoking still worryingly high: Girls twice as likely as boys to puff away
7. Smallpox vaccine can be diluted and still be effective, expanding supply if needed
8. Beneficiaries with chronic conditions still face high costs under new Medicare drug law
9. Hormone therapy may still offer important health benefits to postmenopausal women
10. APA poll: Most Americans have sought mental health treatment but cost, insurance still barriers
11. If core breast biopsy shows minimal abnormal cells, surgical excision is still necessary

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2016)... Florida (PRWEB) , ... May 31, 2016 , ... ... Jay Butch of CertainTeed Corporation, he knew it was something that contractors should ... state-of-the-art and cutting-edge as it gets,” says Butch, CertainTeed’s Director of Contractor Programs. ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only ... the industry as a whole. On June 2, Northbound CEO Mike Neatherton and COO ... (WCSAD) and presenting the opening plenary on “Leadership: The Journey to Authenticity” with Onsite ...
(Date:5/31/2016)... ... May 31, 2016 , ... WaterField Designs, an innovative ... announces the waxed-canvas and leather Duo Dopp Kit , the ideal gift upgrade ... ballistic nylon, the Duo is smartly designed for Dad’s grooming routine. Two ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Interest is on ... screening tool and as an orthogonal tool for RNAi hit validation. A key reason ... specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. ...
(Date:5/31/2016)... Tel Aviv (PRWEB) , ... May 31, 2016 ... ... in the May 4, 2016 Cool Vendors in Security Infrastructure Protection report by ... areas and publishes a series of research reports evaluating these innovative vendors and ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Hutchison China MediTech (Chi-Med) ... the highly lucrative global oncology and immunology markets. ... first-in-class or best-in-class tyrosine kinase inhibitor (TKI) drugs, ... partners. HCM,s profitable Chinese healthcare business continues to ... progress of the mid-to-late-stage pipeline during 2016-17 (including ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... , May 26, 2016 ... has matured into an essential life science tool for ... development applications. BCC Research reveals in its new report ... second growth phase, one powered by a range of ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Medicine Technology:
Cached News: